EAGLE PHARMACEUTICALS, INC. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenue
Product sales, net
Royalty revenue
License and other revenue
Total revenue
Operating expenses:
Cost of product sales
Cost of royalty revenue
Research and development
Selling, general and administrative
Restructuring charge
Gain on sale of asset
Asset impairment charge
Change in fair value of contingent consideration
Legal settlement
Total operating expenses

Income from operations
Interest income
Interest expense
Other expense
Total other expense, net
Income (loss) before income tax provision
Income tax provision
Net income (loss)
Earnings (Loss) per common share:
Basic (in dollars per share)
Diluted (in dollars per share)
Weighted average number of common shares outstanding:
Basic (in shares)
Diluted (in shares)

Comments